1. Home
  2. DYN
  3. DYN News

Latest Dyne Therapeutics Inc. (DYN) News on April 24, 2025

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
DYN

Investor's Business Daily

2 days ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
DYN

GlobeNewswire

9 days ago

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DYN

GlobeNewswire

9 days ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m
DYN

Simply Wall St.

14 days ago

Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m

DYN

MT Newswires

21 days ago

RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk

Biotech stocks slide as Marks resignation seen being negative for sector
DYN

TipRanks

23 days ago

Biotech stocks slide as Marks resignation seen being negative for sector

DYN

MT Newswires

a month ago

Sector Update: Health Care Stocks Steady Premarket Friday

DYN

MT Newswires

a month ago

Dyne Therapeutics Names Erick Lucera as CFO

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
DYN

GlobeNewswire

a month ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
DYN

GlobeNewswire

a month ago

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

DYN

MT Newswires

a month ago

Sector Update: Health Care Stocks Decline Premarket Monday

DYN

MT Newswires

a month ago

Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
DYN

GlobeNewswire

a month ago

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
DYN

Benzinga

a month ago

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating
DYN

GuruFocus.com

a month ago

BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating

DYN

MT Newswires

a month ago

BMO Capital Initiates Dyne Therapeutics Inc at Outperform With $50 Price Target

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
DYN

GlobeNewswire

a month ago

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

DYN

MT Newswires

2 months ago

RBC Cuts Price Target on Dyne Therapeutics to $41 From $45, Keeps Outperform, Speculative Risk

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?
DYN

Simply Wall St.

2 months ago

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

DYN

MT Newswires

2 months ago

Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
DYN

GlobeNewswire

2 months ago

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
DYN

GlobeNewswire

2 months ago

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)
DYN

Zacks

2 months ago

After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)

Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now
DYN

Insider Monkey

3 months ago

Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
DYN

GlobeNewswire

3 months ago

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
DYN

Zacks

3 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
DYN

Zacks

3 months ago

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround
DYN

Zacks

3 months ago

Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround

DYN

MT Newswires

3 months ago

Dyne Therapeutics Says US FDA Grants Fast Track tag to Neuromuscular Disease Therapy

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
DYN

GlobeNewswire

3 months ago

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

DYN

MT Newswires

3 months ago

Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026
DYN

GlobeNewswire

3 months ago

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
DYN

GlobeNewswire

3 months ago

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
DYN

GlobeNewswire

3 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

DYN

MT Newswires

4 months ago

Baird Initiates Dyne Therapeutics at Outperform With $46 Price Target

DYN

MT Newswires

5 months ago

RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target

Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
DYN

Insider Monkey

5 months ago

Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

DYN

MT Newswires

5 months ago

Dyne Therapeutics' Q3 Loss Narrows

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
DYN

GlobeNewswire

5 months ago

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

DYN

MT Newswires

6 months ago

JPMorgan Downgrades Dyne Therapeutics to Neutral From Overweight, Adjusts Price Target to $35 From $43

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
DYN

GlobeNewswire

6 months ago

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now
DYN

Insider Monkey

7 months ago

Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
DYN

GlobeNewswire

7 months ago

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

DYN

MT Newswires

7 months ago

Dyne Therapeutics Insider Sold Shares Worth $308,864, According to a Recent SEC Filing

CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares
DYN

Simply Wall St.

8 months ago

CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares

Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
DYN

Zacks

8 months ago

Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More

DYN

MT Newswires

8 months ago

Dyne Therapeutics Insider Bought Shares Worth $1,057,216, According to a Recent SEC Filing

Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
DYN

Zacks

8 months ago

Dyne Reports Mixed Data From DMD Study, Key Executives Step Down

High-dose Spinraza meets study goal; Top Dyne executives exit
DYN

BioPharma Dive

8 months ago

High-dose Spinraza meets study goal; Top Dyne executives exit

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
DYN

Investor's Business Daily

8 months ago

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
DYN

Benzinga

8 months ago

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy

DYN

MT Newswires

8 months ago

Dyne Therapeutics Duchenne Muscular Dystrophy Drug Study Shows Improvements -- Shares Tumble

Dyne Therapeutics Announces Key Leadership Appointments
DYN

GlobeNewswire

8 months ago

Dyne Therapeutics Announces Key Leadership Appointments

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
DYN

GlobeNewswire

8 months ago

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
DYN

GlobeNewswire

8 months ago

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

DYN

MT Newswires

8 months ago

Chardan Adjusts Price Target on Dyne Therapeutics to $50 From $42, Maintains Buy Rating

DYN

MT Newswires

8 months ago

Dyne Therapeutics Q2 Loss Narrows

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
DYN

GlobeNewswire

8 months ago

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why
DYN

Zacks

9 months ago

Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why

What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
DYN

Zacks

9 months ago

What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?

Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
DYN

Zacks

9 months ago

Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why

DYN

MT Newswires

9 months ago

JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating

DYN

MT Newswires

10 months ago

Dyne Therapeutics Insider Sold Shares Worth $1,401,902, According to a Recent SEC Filing

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
DYN

GlobeNewswire

10 months ago

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

DYN

MT Newswires

10 months ago

Dyne Therapeutics Insider Sold Shares Worth $1,334,201, According to a Recent SEC Filing

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
DYN

GlobeNewswire

10 months ago

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

DYN

MT Newswires

10 months ago

Dyne Therapeutics Insider Sold Shares Worth $2,583,782, According to a Recent SEC Filing

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities
DYN

GlobeNewswire

10 months ago

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)
DYN

Motley Fool

10 months ago

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans
DYN

CNW Group

10 months ago

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike
DYN

Investor's Business Daily

10 months ago

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

EPCOR and HAWSCo Enter Ownership Transfer Agreement
DYN

CNW Group

10 months ago

EPCOR and HAWSCo Enter Ownership Transfer Agreement

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate
DYN

GlobeNewswire

10 months ago

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

Southwest Airlines stock pops on report of Elliott's $2B stake
DYN

Yahoo Finance Video

10 months ago

Southwest Airlines stock pops on report of Elliott's $2B stake

DYN

Business Wire

10 months ago

Form 8.3 - Virgin Money UK plc

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
DYN

GOBankingRates

10 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
DYN

Business Insider

10 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women
DYN

Insider Monkey

10 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
DYN

Reuters

10 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

DYN

Insider Monkey

10 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow
DYN

AFP

10 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events
DYN

Investor's Business Daily

10 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments
DYN

The Wall Street Journal

10 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
DYN

GlobeNewswire

a year ago

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
DYN

GlobeNewswire

a year ago

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

DYN

MT Newswires

a year ago

Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing

DYN

MT Newswires

a year ago

Dyne Therapeutics Prices $325.5 Million Common Stock Offering

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
DYN

GlobeNewswire

a year ago

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
DYN

Zacks

a year ago

Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies

DYN

MT Newswires

a year ago

Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept

Why Is Dyne Therapeutics Stock Soaring On Monday?
DYN

Benzinga

a year ago

Why Is Dyne Therapeutics Stock Soaring On Monday?

DYN

MT Newswires

a year ago

Dyne Therapeutics Launches $300 Million Share Offering

Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again
DYN

Investor's Business Daily

a year ago

Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again

Dyne Therapeutics Announces Proposed Public Offering of Common Stock
DYN

GlobeNewswire

a year ago

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

DYN

MT Newswires

a year ago

Update: Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles

DYN

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating

DYN

MT Newswires

a year ago

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

Dyne shares jump on trial data for muscle disease drugs
DYN

BioPharma Dive

a year ago

Dyne shares jump on trial data for muscle disease drugs

DYN

MT Newswires

a year ago

Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
DYN

GlobeNewswire

a year ago

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

Share on Social Networks: